1. Home
  2. RBC vs INCY Comparison

RBC vs INCY Comparison

Compare RBC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RBC Bearings Incorporated

RBC

RBC Bearings Incorporated

HOLD

Current Price

$581.00

Market Cap

18.0B

Sector

Industrials

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$97.44

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBC
INCY
Founded
1919
1991
Country
United States
United States
Employees
5334
N/A
Industry
Metal Fabrications
Biotechnology: Commercial Physical & Biological Resarch
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0B
17.0B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
RBC
INCY
Price
$581.00
$97.44
Analyst Decision
Buy
Buy
Analyst Count
6
21
Target Price
$510.00
$103.52
AVG Volume (30 Days)
219.8K
1.2M
Earning Date
05-15-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
4173.33
EPS
N/A
1.47
Revenue
N/A
$3,394,635,000.00
Revenue This Year
$15.20
$10.44
Revenue Next Year
$12.36
$10.99
P/E Ratio
$64.90
$66.16
Revenue Growth
N/A
13.67
52 Week Low
$355.47
$63.93
52 Week High
$632.00
$112.29

Technical Indicators

Market Signals
Indicator
RBC
INCY
Relative Strength Index (RSI) 49.45 51.42
Support Level $574.08 $93.17
Resistance Level $598.31 $103.11
Average True Range (ATR) 19.89 2.45
MACD -4.87 -0.15
Stochastic Oscillator 42.77 37.04

Price Performance

Historical Comparison
RBC
INCY

About RBC RBC Bearings Incorporated

RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: